Seeking Alpha

Idenix Pharmaceuticals (IDIX) -9.6% after Stifel Nicolaus downgrades shares to Sell from Hold at...

Idenix Pharmaceuticals (IDIX) -9.6% after Stifel Nicolaus downgrades shares to Sell from Hold at Stifel Nicolaus, which believes the "significant difference" in potency existing between IDIX's hepatitis C drug and those made by Pharmasset (VRUS) and Inhibitex (INHX) has important implications on how remaining "potential consolidators" strategically view the companies.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|